UNSPSC 51412602: Todralazine

This classification denotes a vasodilating agent with the molecular formula C11H12N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WEN3K83YKD, chemically known as hydrazinecarboxylic acid, 2-(1-phthalazinyl)-, ethyl ester (9ci) but generally known as todralazine, which bears US NIH Compound Identifier 5501. European Medicines Agency schedules Todralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11141MIG. The term TODRALAZINE is an International Non-Proprietary Name.

UNSPSC 51412602 Todralazine, a Commodity code, encompasses pharmaceutical supply contracts where state and local governments procure branded and generic medications for emergency medical services, hospital systems, and public health programs. Recent solicitations show state and local buyers sourcing advanced life support medications, generic multi-source pharmaceuticals, and OTC products through a mix of direct municipal procurement, cooperative purchasing vehicles, and exploratory state health agency programs. The scope spans individual medication line items (vials, injections, doses) with firm expiration-date requirements, safety data sheet compliance, and performance warranties, as well as broader pharmaceutical supply frameworks negotiated through wholesaler networks and group purchasing arrangements.

Issuing bodies include municipal fire rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances. The City of Tampa's Fire Rescue department issued IFB No. 26P00188 on April 24, 2026, for advanced life support medications (Labetalol, Epinephrine, Adenosine, Diltiazem) with a response deadline of April 8, 2026, and an estimated contract value of $40,000, including a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP No. S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota and Oregon, with a March 26, 2026, response deadline. The Texas Health and Human Services Commission issued RFI No. HHS0017013 on April 3, 2026, to explore direct-to-manufacturer prescription program capabilities. Recent activity concentrates in Florida, Minnesota, and Texas, with cooperative purchasing extending across multiple states.